CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies Operator Experience and Outcomes After Left Main Percutaneous Coronary Intervention A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF) Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial Frailty and Bleeding in Older Adults Undergoing TAVR or SAVR: Insights From the FRAILTY-AVR Study Percutaneous Atriotomy for Levoatrial–to–Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human Experience Bridging the Gap Between Epigenetic and Genetic in PAH Aortic Valve Stenosis Treatment Disparities in the Underserved JACC Council Perspectives Serial intravascular ultrasound assessment of very late stent thrombosis after sirolimus-eluting stent placement The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE

Original Research2018 Jan 23. [Epub ahead of print]

JOURNAL:Catheter Cardiovasc Interv. Article Link

Prevalence, Presentation and Treatment of 'Balloon Undilatable' Chronic Total Occlusions: Insights from a Multicenter US Registry

Tajti P, Karmpaliotis D, Alaswad K et al. Keywords: chronic total occlusion; complex coronary intervention; percutaneous coronary intervention

ABSTRACT


Background - The prevalence, treatment and outcomes of balloon undilatable chronic total occlusions (CTOs) have received limited study.


Methods - We examined the prevalence, clinical and angiographic characteristics, and procedural outcomes of percutaneous coronary interventions (PCIs) for balloon undilatable CTOs in a contemporary multicenter US registry.


Results - Between 2012 and 2017 data on balloon undilatable lesions were available for 425 consecutive CTO PCIs in 415 patients in whom guidewire crossing was successful: 52 of 425 CTOs were balloon undilatable (12%). Mean patient age was 65 ± 10 years and most patients were men (84%). Patients with balloon undilatable CTOs were more likely to be diabetic (67 vs. 41%, P< 0.001) and have heart failure (44 vs. 28%, P= 0.027). Balloon undilatable CTOs were longer (40 mm [interquartile range, IQR 20-50] vs. 30 [IQR 15-40], P= 0.016), more likely to have moderate/severe calcification (87 vs. 54%, P< 0.001), and had higher J-CTO score (3.2 ± 1.1 vs. 2.5 ± 1.3, P< 0.001) and PROGRESS-CTO complications score (3.9 ± 1.7 vs. 3.1 ± 2.0, P< 0.005). They were associated with lower technical and procedural success (92 vs. 98%, P= 0.024; and 88 vs. 96%, P= 0.034, respectively) and higher risk for in-hospital major adverse events (8 vs. 2%, P= 0.008) due to higher perforation rates. The most frequent treatments for balloon undilatable CTOs were high pressure balloon inflations (64%), rotational atherectomy (31%), laser (21%), and cutting balloons (15%).


Conclusions - Balloon undilatable CTOs are common and are associated with lower success and higher complication rates.


Clinical Trial Registration - NCT02061436, Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS CTO)


© 2018 Wiley Periodicals, Inc.